Chronic NK cell activation results in a dysfunctional, tissue resident–like state mediated by KLF2 deficiency

J Jacob A. Myers (1Masonic Cancer Center, University of Minnesota, Minneapolis, MN) R Rih-Sheng Huang (1Masonic Cancer Center, University of Minnesota, Minneapolis, MN) S Shee Kwan Phung (1Masonic Cancer Center, University of Minnesota, Minneapolis, MN) J Jeremy M. Chacón (2Research and Innovation Office, Minnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN) L Laura Bendzick (1Masonic Cancer Center, University of Minnesota, Minneapolis, MN) A Anna Weis (1Masonic Cancer Center, University of Minnesota, Minneapolis, MN) M Mihir Shetty T Taylor A. DePauw (Center for Immunology, University of Minnesota Medical School) M Melissa J. Khaw (1Masonic Cancer Center, University of Minnesota, Minneapolis, MN) J Juan E. Abrahante (2Research and Innovation Office, Minnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN) S Stephen D. O’Flanagan (3Department of Laboratory Medicine and Pathology, Center for Immunology, University of Minnesota Medical School, Minneapolis, MN) K K. Maude Ashby (4Allergy Division, Feinberg School of Medicine, Northwestern University, Chicago, IL) J John R. Lozada (1Masonic Cancer Center, University of Minnesota, Minneapolis, MN) S Stephen C. Jameson (Center for Immunology, University of Minnesota Medical School) J Justin H. Hwang F Frank Cichocki (1Masonic Cancer Center, University of Minnesota, Minneapolis, MN) M Martin Felices (1Masonic Cancer Center, University of Minnesota, Minneapolis, MN) J Jeffrey S. Miller (1Masonic Cancer Center, University of Minnesota, Minneapolis, MN)

Abstract

Abstract Adoptive transfer of natural killer (NK) cells can induce complete remissions in 30% to 50% of patients with refractory acute myeloid leukemia and lymphoma. Although blood chimerism occurs, attaining functional homing to the site of tumor without exhaustion has been elusive. During chronic infections and tumorigenesis, exposure to activating stimuli weakens the effector activity of NK cells. Despite this knowledge, there is little known about the mechanisms that govern this dysregulation and whether these disparate activating stimuli use distinct pathways to downregulate effector immunity. In this study, we reveal that chronic NK cell activation receptor (NKAR) stimulation and chronic interleukin-15 exposure impart distinct modes of dysregulation, with NKAR stimulation inducing a tissue resident–like state that resembles that of tumor-infiltrating NK cells in patients with cancer. Using loss- and gain-of-function studies, we identify the transcription factor KLF2 as a master regulator of the NK cell response to chronic activation and provide evidence that KLF2 overexpression promotes NK cell cytotoxicity, cytokine production, and chemotaxis and inhibits the development of dysfunctional, tissue resident–like features. Using KLF2 reporter mice, we show that in certain tissues, tissue resident NK cells are predominantly KLF2–, whereas circulating NK cells in these tissues are overwhelmingly KLF2+. Lastly, using mixed bone marrow chimeras, we demonstrate that conditional KLF2 deficiency in NK cells leads to altered homing and the acquisition of tissue resident–like features in vivo. Together, these findings highlight the profound changes NK cells undergo during prolonged activation and advance our understanding of how some NK cell therapies fail during malignant relapse.

Article Details

Journal Blood
Volume / Issue Vol. 146, Issue 25
Published December 18, 2025
Pages 3059-3071
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (18)

J

Jacob A. Myers

1Masonic Cancer Center, University of Minnesota, Minneapolis, MN

R

Rih-Sheng Huang

1Masonic Cancer Center, University of Minnesota, Minneapolis, MN

S

Shee Kwan Phung

1Masonic Cancer Center, University of Minnesota, Minneapolis, MN

J

Jeremy M. Chacón

2Research and Innovation Office, Minnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN

L

Laura Bendzick

1Masonic Cancer Center, University of Minnesota, Minneapolis, MN

A

Anna Weis

1Masonic Cancer Center, University of Minnesota, Minneapolis, MN

M

Mihir Shetty

T

Taylor A. DePauw

Center for Immunology, University of Minnesota Medical School

M

Melissa J. Khaw

1Masonic Cancer Center, University of Minnesota, Minneapolis, MN

J

Juan E. Abrahante

2Research and Innovation Office, Minnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN

S

Stephen D. O’Flanagan

3Department of Laboratory Medicine and Pathology, Center for Immunology, University of Minnesota Medical School, Minneapolis, MN

K

K. Maude Ashby

4Allergy Division, Feinberg School of Medicine, Northwestern University, Chicago, IL

J

John R. Lozada

1Masonic Cancer Center, University of Minnesota, Minneapolis, MN

S

Stephen C. Jameson

Center for Immunology, University of Minnesota Medical School

J

Justin H. Hwang

F

Frank Cichocki

1Masonic Cancer Center, University of Minnesota, Minneapolis, MN

M

Martin Felices

1Masonic Cancer Center, University of Minnesota, Minneapolis, MN

J

Jeffrey S. Miller

1Masonic Cancer Center, University of Minnesota, Minneapolis, MN